APS 2012 Booth Presentation: A Novel Approach to Drug Screening with Blood


Interpretation of urine opioid test results depends on the proportional relationship of parent drugs and drug metabolites. Such patterns are generally used to verify that a patient has been compliant with prescribed therapy, but may also be used to identify when patients have added a drug directly to urine to mimic compliance. This presentation will discuss typical and atypical patterns of buprenorphine and associated metabolite concentrations in urine, relative to the most likely interpretations regarding compliance with therapy.

Originally presented on May 18, 2012, in Honolulu, Hawaii.

Lecture Presenter

Gwendolyn A. McMillin, PhD

Gwendolyn A. McMillin, PhD

Medical Director, Toxicology and Trace Elements Laboratories
ARUP Laboratories
Co-Medical Director, Pharmacogenetics
ARUP Laboratories
Associate Professor of Pathology
University of Utah School of Medicine

Dr. McMillin is a medical director of the Toxicology and Trace Elements laboratories and co-medical director of Pharmacogenetics at ARUP, as well as an associate professor of pathology at the University of Utah School of Medicine. She received her PhD in pharmacology and toxicology from the University of Utah and is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry.

Sponsored by:

University of Utah School of Medicine, and ARUP Laboratories